Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover image insert - p. iii 7. Aims and scope of series “Breaking tolerance to antibody-targeted therapies” - p. iii 8. About the Series Editor - p. iii 9. Aims and scope of the volume “Overcoming Cancers Resistant to HER-2 Antibodies” - p. iii 10. Preface “Overcoming Cancers Resistant to HER-2 Antibodies” - p. xiii 11. Contributors - p. xxi 12. Chapter 1. Resistance of breast cancer brain metastasis to trastuzumab therapy - p. 11 13. Chapter 2. Resistance of HER2-expressing breast cancer patients treated with trastuzumab: Underlying mechanisms of resistance and reversals - p. 19 14. Chapter 3. Understanding mechanisms of resistance to HER2-targeted therapies in HER2-positive breast cancer - p. 45 15. Chapter 4. Clinical implications and management strategies of resistance to anti-HER2 antibodies in breast cancer - p. 57 16. Chapter 5. Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer - p. 69 17. Chapter 6. How does understanding epigenetics help circumvent HER-2 antibody resistance? - p. 114 18. Chapter 7. Resistance of HER2-expressing ovarian cancer to trastuzumab and mechanisms of overcoming resistance - p. 127 19. Chapter 8. Clinical implications of resistance to anti-HER2 antibodies in breast cancer - p. 170 20. Chapter 9. Highlights of current and future for the treatment of resistant HER2+ breast cancer to HER2-targeted therapies - p. 189 21. Index - p. 199
Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover image insert - p. iii 7. Aims and scope of series “Breaking tolerance to antibody-targeted therapies” - p. iii 8. About the Series Editor - p. iii 9. Aims and scope of the volume “Overcoming Cancers Resistant to HER-2 Antibodies” - p. iii 10. Preface “Overcoming Cancers Resistant to HER-2 Antibodies” - p. xiii 11. Contributors - p. xxi 12. Chapter 1. Resistance of breast cancer brain metastasis to trastuzumab therapy - p. 11 13. Chapter 2. Resistance of HER2-expressing breast cancer patients treated with trastuzumab: Underlying mechanisms of resistance and reversals - p. 19 14. Chapter 3. Understanding mechanisms of resistance to HER2-targeted therapies in HER2-positive breast cancer - p. 45 15. Chapter 4. Clinical implications and management strategies of resistance to anti-HER2 antibodies in breast cancer - p. 57 16. Chapter 5. Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer - p. 69 17. Chapter 6. How does understanding epigenetics help circumvent HER-2 antibody resistance? - p. 114 18. Chapter 7. Resistance of HER2-expressing ovarian cancer to trastuzumab and mechanisms of overcoming resistance - p. 127 19. Chapter 8. Clinical implications of resistance to anti-HER2 antibodies in breast cancer - p. 170 20. Chapter 9. Highlights of current and future for the treatment of resistant HER2+ breast cancer to HER2-targeted therapies - p. 189 21. Index - p. 199
